srch

Contact us. Blueprint Medicines Global Headquarters. 45 Sidney Street. Cambridge, MA 02139. (617) 374-7580. info@blueprintmedicines.com. EU Office. Blueprint Medicines (Switzerland) GmbH. Baarerstrasse 8.

15.12.2021 · The corporate mailing address for Dr. Namouni and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]

Primary IR Contact. Kristin Hodous Blueprint Medicines Phone: 617-714-6674. Email: khodous@blueprintmedicines.com. To request information, please fill out ...

28.07.2021 · MD Anderson and Blueprint Medicines will jointly design translational studies, and Blueprint Medicines will provide funding, research compounds and additional support. As part of the agreement, MD Anderson is eligible to receive certain payments based on the future development of BLU-222.

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations

SEC CIK #0001597264 ; SIC, 2834 [PHARMACEUTICAL PREPARATIONS] ; Business Address. 45 SIDNEY STREET. CAMBRIDGE MA 02139 ; Business Phone, 617-374-7580 ; Mailing ...

Blueprint Medicines Office Locations ; Cambridge · US · 45 Sidney St ; Cambridge · US. 38 Sidney St #200 ; Amsterdam · NL. Gustav Mahlerplein 2 ; Lugano · CH. Via Emilio ...

Contract #:, 36F79720D0179. Contractor: BLUEPRINT MEDICINES, INC. Address: 45 SIDNEY ST CAMBRIDGE, MA 02139. Phone: 857-209-3092.

Company Description: Blueprint Medicines is a precision therapy company that ... Address: 45 Sidney St Cambridge, MA, 02139-4133 United States See other ...

Blueprint Medicines Corporation develops and distributes biomedical treatments. The Company researches and produces medicines and treatments for cancer ...

09.11.2021 · Blueprint Medicines Corporation (NASDAQ: BPMC) and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and ...

03.12.2021 · Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition ...

07.12.2021 · Shares of Blueprint Medicines Co. (NASDAQ:BPMC) have been given a consensus recommendation of "Buy" by the twelve research firms that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy …

Blueprint Medicines Corp headquarters address, phone number and website information and details on other Blueprint Medicines Corp's locations and ...

We have found Blueprint Medicines to be using 3 different formats for professional email addresses. The most common email pattern is {f}{last}@blueprintmedicines.com, e.g. dcooper@blueprintmedicines.com, which is used for 37.5% of all work email addresses at blueprintmedicines.com. Some other patterns used are {first}.{last}@blueprintmedicines.com …

At Blueprint Medicines, we work together in pursuit of one common goal: to ... so we can develop patient-centric strategies to address medical needs.

Blueprint Medicines (Germany) GmbH, Munich, Germany, District Court of Munich HRB 245574: Network, Financial information. ... If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company. ...

25.09.2019 · The visualizations for "Blueprint Medicines (Germany) GmbH - Name · Address · Managing Director: Jeffrey W. Albers, Michael Landsittel, Paul M. Beresford · No longer Managing Director: Antje Borcherdt · Corporate Purpose · Company statute" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.